ArticleCase reports in rheumatology2025
Subcutaneous Emphysema and Severe Interstitial Lung Disease in the Setting of Anti-MDA 5 Positive Dermatomyositis in a Hispanic Patient.
Article in Case reports in rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Case series: Interstitial lung disease with IPF pattern presenting with spontaneous pneumothorax-clinical course of two patients.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimelanoma differentiation-associated gene 5 (MDA5) dermatomyositis (DM) is a subtype of DM associated with characteristic mucocutaneous features. These individuals have an increased risk of developing interstitial lung disease (ILD) that ultimately leads to a complicated clinical course. Certain clinical findings suggest anti-MDA5 positive DM over anti-MDA5 negative DM, including cutaneous ulcers, diffuse nonscarring alopecia, and panniculitis. ILD and pneumomediastinum are known to be two of the most important pulmonary complications of anti-MDA5 DM because of the possibility of a rapidly progressive course and poor survival. This case outlines the unique presentation of pneumomediastinum, subcutaneous emphysema, and ILD in a patient with anti-MDA5 positive DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.